Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleed...
Huadu District People's Hospital of Guangzhou, Guangzhou, China
The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
University of California, San Francisco, San Francisco, California, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Shamir Medical Center, Be'er Ya'aqov, Israel
Hebei Medical University Third Hospital, Shijiazhuang, Hebei, China
Mbeya Regional Referral Hospital, Mbeya, Tanzania
AMITA Health Saint Joseph Chicago, Chicago, Illinois, United States
Northwestern Memorial Hospital, Chicago, Illinois, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.